10 Years of SurVaxM

In 10 short years, donor support helped bring a homegrown cancer-fighting discovery to the national stage in the form of a clinical trial. SurVaxM, a therapeutic cancer vaccine developed at Roswell Park Comprehensive Cancer Center, has the potential to drastically extend the lives of patients living with brain cancer. You and your donors are part of that.

SurVaxM was created in a lab at Roswell Park by Robert Fenstermaker, MD, Chair of Neurosurgery and Michael Ciesielski, PhD, Assistant Professor of Neurosurgery. Dr. Fenstermaker is the Principal Investigator of the nationwide randomized trial and Dr. Ciesielski is CEO of MimiVax, the company which now produces SurVaxM. Their work has been passionately supported by donor funding for the past 10 years, proving instrumental in bringing this new treatment to where it is today.

Robert Fenstermaker, MD, Chair of Neurosurgery and Michael Ciesielski, PhD, with a sample of SurVaxM

2012

Roswell Park announces a new clinical research study that could put cancer cells “in a Catch-22.”

2013

A phase I clinical trial begins in human patients, supported by the American Cancer Society.

SurVaxM
SurVaxM lab image

2014

Roswell Park donors begin to financially support SurVaxM alongside the Roswell Park Alliance Foundation through events like Ride for Roswell and more.

2015

Drs. Fenstermaker and Ciesielski present their phase I clinical trial results to the American Association for Cancer Research Annual Meeting in Philadelphia.

Phase II of the clinical trial begins, bringing hope to 50 newly diagnosed patients at Roswell Park and Cleveland Clinic.

Ciesielski and Fenstermaker in the lab
SurVaxM

2016

Experts investigate usefulness of SurVaxM for patients with multiple myeloma.

2017

The U.S. Food and Drug Administration (FDA) awards orphan drug status for SurVaxM. This designation is intended to encourage innovation in the treatment of rare diseases.

Dr. Ciesielski SurVaxM lab image
Ciesielski and Fenstermaker in the lab

2018

Findings through SurVaxM trials open doors for other types of treatments like CAR T-cell therapy and antibody-based therapies.

Drs. Fenstermaker and Ciesielski join their colleagues at Cleveland Clinic to present their phase II findings so far at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Results from phase II clinical trial show significant success: well-tolerated; 96.7% of patients did not experience disease progression within the first six months; 94.2% of study participants were alive one year after their diagnosis, as opposed to 65% of patients in a historical comparison group.

2019

Trial leaders bring fully completed results to the ASCO Annual Meeting.

Roswell Park and MimiVax announce the next step forward: a larger scale phase II study and a licensing agreement.

SurVaxM lab image
Dr. Renuka Iyer

2020

Two new studies, led by Renuka Iyer, MD, of Roswell Park, explore the potential use of SurVaxM for patients with neuroendocrine tumors.

2022

SurVaxM

2023

The FDA grants Fast Track Designation for SurVaxM, opening doors to accelerated approval as late-stage clinical trials advance.

2024

You fundraise for Ride for Roswell, armed with the confidence that your hard work is propelling something meaningful on a national scale.

Want to learn more about your impact?

Contact our team at rideforroswell@roswellpark.org.